Epstein–Barr virus‐associated lymphomas decoded
Open Access
- 28 December 2023
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 204 (2) , 415-433
Abstract
Summary: Epstein–Barr virus (EBV)‐associated lymphomas cover a range of histological B‐ and T‐cell non‐Hodgkin and Hodgkin lymphoma subtypes. The role of EBV on B‐cell malignant pathogenesis and its impact on the tumour microenvironment are intriguing but incompletely understood. Both the International Consensus Classification (ICC) and 5th Edition of the World Health Organization (WHO‐HAEM5) proposals give prominence to the distinct clinical, prognostic, genetic and tumour microenvironmental features of EBV in lymphoproliferative disorders. There have been major advances in our biological understanding, in how to harness features of EBV and its host immune response for targeted therapy, and in using EBV as a method to monitor disease response. In this article, we showcase the latest developments and how they may be integrated to stimulate new and innovative approaches for further lines of investigation and therapy.Keywords
Funding Information
- Mater Foundation
This publication has 155 references indexed in Scilit:
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted TherapyClinical Cancer Research, 2012
- Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agentsBlood, 2012
- AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?Blood, 2010
- Allelic polymorphism in the T cell receptor and its impact on immune responsesJournal of Experimental Medicine, 2010
- EBV Is Necessary for Proliferation of Dually Infected Primary Effusion Lymphoma CellsCancer Research, 2008
- Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognitionProceedings of the National Academy of Sciences, 2008
- Galectin-1 mediated suppression of Epstein-Barr virus–specific T-cell immunity in classic Hodgkin lymphomaBlood, 2007
- A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus–associated lymphoid malignanciesBlood, 2006
- Resting B cells as a transfer vehicle for Epstein–Barr virus infection of epithelial cellsProceedings of the National Academy of Sciences, 2006
- A sarcoma involving the jaws in african childrenBritish Journal of Surgery, 1958